# Fm 2016 Crack Mkdev Fm2016 72

Download

nvram kaiymele 27 avr, 2026 . /1035-cocoa-fundamentals-5th-edition-eap/ An evaluation of a new phenylpropanolamine-type peripheral alpha-adrenoceptor antagonist using the dog. The alpha-adrenoceptor antagonist activity of (Z)-7-(2-{(dimethylamino)methylene}-1,3-dioxol-4-yl)-2-(phenyl-1-propenyl)-1,2,3,4-tetrahydro-naphthalene-1-ol hydrochloride (1) was investigated in anaesthetized dogs. The receptor binding affinity of 1 and two structurally related compounds (2, 2'-dihydro-2-methyl-2'-(2-methylphenyl)-2,2'-dihydroxy-6-benzyl-5,6-dihydro-1,2-naphthyl-propane-1,2-diol hydrochloride (2) and 2'-(2-methylphenyl)-6-(1,3-benzodioxol-5-yl)-1,2,3,4-tetrahydro-naphthalene-1-ol hydrochloride (3)) for cloned alpha-1, alpha-2, beta-1 and beta-2 adrenoceptors was studied and compared with that of phenoxybenzamine. In addition, the acute and chronic effects of these agents on the electrocardiogram, arterial blood pressure and blood flow were determined. In the anaesthetized dog, the i.v. administration of 1 (0.5-4 mg kg-1) produced an increase in heart rate and a decrease in the blood pressure, which was closely correlated with the inhibition of regional vascular bed blood flow induced by phenylephrine (0.01-0.2 mg kg-1, i.v.). The half-life of 1 following i.v. administration was about 40 min in this preparation. The antagonist effect of 1 was not antagonized by yohimbine or atropine and was not altered after chronic treatment. This study shows that 1 is a potent peripheral alpha-adrenoceptor antagonist with a longer half-life than the phenoxybenzamine analogue.(ABSTRACT TRUNCATED AT

2d92ce491b